Pune: New and emerging therapies, which cause less collateral damage to normal blood and target specific mutations, are a ...

Acute Myeloid Leukemia (AML), an aggressive form of blood cancer, has long been a significant challenge for patients and doctors in India. But recent medical breakthroughs—including the recent approva ...

Acute Myeloid leukaemia AML is a fast-growing cancer of the bone marrow that disrupts blood cell production It differs from ...

What begins as mere tiredness, a lingering fever, or unexplained bruises could be a sign of something far more serious. June is observed globally as Acute Myeloid Leukaemia (AML) Awareness Month, ...

Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an ...

June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick ...

It was acquired by Servier alongside IDH inhibitor stablemate Tibsovo (ivosidenib), which is already approved to treat acute myeloid leukaemia.

FDA and EMA start speedy reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, hoping to end decades of stagnation in therapies for the brain cancer.

Ivosidenib (Tibsovo ®) is a type of targeted therapy drug called a cancer growth inhibitor. Azacitidine is a chemotherapy drug. Ivosidenib and azacitidine treatment is used to treat acute myeloid ...